In situ preparation and fate of cis-4-hydroxycyclophosphamide and aldophosphamide: 1H and 31P NMR evidence for equilibration of cis- and trans-4-hydroxycyclophosphamide with aldophosphamide and its hydrate in aqueous solution
- PMID: 6708051
- DOI: 10.1021/jm00370a010
In situ preparation and fate of cis-4-hydroxycyclophosphamide and aldophosphamide: 1H and 31P NMR evidence for equilibration of cis- and trans-4-hydroxycyclophosphamide with aldophosphamide and its hydrate in aqueous solution
Abstract
cis-4-Hydroxycyclophosphamide (2) and aldophosphamide (4) were generated in aqueous phosphate or cacodylate buffer by dimethyl sulfide reduction of cis-4-hydroperoxycyclophosphamide (8) and by sodium periodate cleavage of 3,4-dihydroxybutyl N,N-bis(2-chloroethyl)phosphorodiamidate (9), respectively; the reactions of 2 and 4 were examined by 1H and 31P NMR. Within 30-60 min (pH or pD 7.0, 25 degrees C) the same pseudoequilibrium mixture was established in both reactions, with cis- and trans-4-hydroxycyclophosphamide (2 and 3), aldophosphamide (4), and its hydrate (5) present in the approximate ratio of 4:2:0.3:1. Structures of the intermediates were assigned unambiguously based upon analysis of the chemical shifts and coupling constants in the proton spectra determined in D2O buffers, and the 31P assignments followed by correlation of component ratios at equilibrium. Free energy differences of 0.4, 0.4, and 0.7 kcal/mol at 25 degrees C were estimated between 2, 3, 5, and 4, respectively, with 2 being the most stable. The aldehyde 4 reacted most rapidly with water to give hydrate 5; cyclization of 4 to 3 occurred faster than to 2, and the rate of cyclization to 2 was comparable to that for elimination to 6. Compound 5 is formed much faster than 3 from the diol cleavage, but 5 and 3 are produced at comparable rates from 2, suggesting that conversion of 2 to 3 can proceed by a mechanism other than ring opening. The rate of equilibration appears to be independent of buffer structure, indicating that bifunctional catalysis is not important in the ring-opening reaction.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
NMR spectroscopic studies of intermediary metabolites of cyclophosphamide. A comprehensive kinetic analysis of the interconversion of cis- and trans-4-hydroxycyclophosphamide with aldophosphamide and the concomitant partitioning of aldophosphamide between irreversible fragmentation and reversible conjugation pathways.J Med Chem. 1984 Apr;27(4):466-85. doi: 10.1021/jm00370a008. J Med Chem. 1984. PMID: 6708049
-
Conversion of 4-hydroperoxycyclophosphamide and 4-hydroxycyclophosphamide to phosphoramide mustard and acrolein mediated by bifunctional catalysis.Cancer Res. 1982 Mar;42(3):830-7. Cancer Res. 1982. PMID: 7059981
-
The mechanism of activation of 4-hydroxycyclophosphamide.J Med Chem. 1987 Feb;30(2):427-31. doi: 10.1021/jm00385a029. J Med Chem. 1987. PMID: 3806624
-
O-Methylhydroxylamine as a new trapping reagent for quantitative studies of 4-hydroxycyclophosphamide and aldophosphamide.J Pharm Sci. 1982 Apr;71(4):443-6. doi: 10.1002/jps.2600710417. J Pharm Sci. 1982. PMID: 7086655
-
The chemistry of the metabolites of cyclophosphamide.Curr Pharm Des. 1999 Aug;5(8):627-43. Curr Pharm Des. 1999. PMID: 10469895 Review.
Cited by
-
Cardiotoxicity of cyclophosphamide's metabolites: an in vitro metabolomics approach in AC16 human cardiomyocytes.Arch Toxicol. 2022 Feb;96(2):653-671. doi: 10.1007/s00204-021-03204-y. Epub 2022 Jan 28. Arch Toxicol. 2022. PMID: 35088106
-
Cyclophosphamides as hypoxia-activated diffusible cytotoxins: a theoretical study.J Comput Aided Mol Des. 2000 May;14(4):307-16. doi: 10.1023/a:1008128023564. J Comput Aided Mol Des. 2000. PMID: 10815768
-
Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays. General considerations, the nitrosoureas and alkylating agents.Cancer Chemother Pharmacol. 1985;14(2):83-95. doi: 10.1007/BF00434343. Cancer Chemother Pharmacol. 1985. PMID: 3882257 Review.
-
The effect of cimetidine on cyclophosphamide metabolism in rabbits.Cancer Chemother Pharmacol. 1990;27(2):125-30. doi: 10.1007/BF00689096. Cancer Chemother Pharmacol. 1990. PMID: 2249327
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Miscellaneous